Immunome (IMNM) CSO Jack Higgins Receives Stock Awards

What Happened

• Jack Higgins, Chief Scientific Officer of Immunome (IMNM), received equity awards on July 23, 2026: 38,250 restricted stock units (RSUs) and 76,500 derivative awards (reported as a derivative grant). Both awards were granted at $0 (no cash exchanged), for a total of 114,750 award shares.
• These are grants/awards (not open-market purchases or sales) and therefore represent compensation awards rather than a buy/sell signal.

Key Details

• Transaction date: July 23, 2026; Form 4 filed July 27, 2026 (filed four days after the transaction date; may be later than the typical 2-business-day Form 4 deadline).
• Grant amounts and prices:
  • 38,250 RSUs @ $0 (footnote F1: each RSU converts to one share upon settlement).
  • 76,500 derivative award units @ $0 (reported as derivative; footnote F3 describes vesting for options-like awards).
• Vesting:
  • RSUs (F1): 25% vest and settle into common stock on each anniversary of the grant date (i.e., annual 25% vesting, subject to continued service).
  • Derivative/option-like award (F3): 25% vests on July 23, 2027, then 1/36th of the remaining amount vests monthly thereafter, subject to continued service.
• Custodial note (F2): The filing indicates Higgins serves as custodian of a custodial account for his child and disclaims beneficial ownership of those shares.
• Shares owned after the transaction: not provided in the supplied filing summary.

Context

• These entries are compensation grants (A = Award/Grant) and should be read as company compensation to the executive, not open-market buying or selling. Such awards are common for executive retention and incentive.
• The derivative award is subject to a vesting schedule; unless otherwise noted, the awards are not immediately tradable until they vest and are settled.